Testicular cancer survivorship: Long-term toxicity and management

Affiliations

¹ Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
² Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
³ Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada.
⁴ Department of Medical Oncology and Hematology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.
⁵ Division of Urology, Department of Surgery, University of Ottawa, Ottawa, ON, Canada.
⁶ Department of Surgical Oncology, Princess Margaret Cancer Centre, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁷ Departments of Urology and Oncology, Queen's University, Kingston, ON, Canada.
⁸ Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Hospital, University of Health Network, University of Toronto, Toronto, ON, Canada.
⁹ Division of Medical Oncology, British Columbia Cancer - Vancouver Cancer Centre, University of British Columbia, Vancouver, BC, Canada.
¹⁰ Department of Supportive Care, Princess Margaret Cancer Centre, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
¹¹ Division of Medical Oncology/Hematology, Le Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
¹² Division of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
¹³ Division of Urology, Department of Surgery, Western University, London, ON, Canada.

PMID: 35905486
PMCID: PMC9343164
DOI: 10.5489/cuaj.8009

Review

Testicular cancer survivorship: Long-term toxicity and management

Noa Shani Shrem et al. Can Urol Assoc J. 2022 Aug.

. 2022 Aug;16(8):257-272.

doi: 10.5489/cuaj.8009.

Authors

Affiliations

¹ Division of Medical Oncology, Department of Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada.
² Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre, Dalhousie University, Halifax, NS, Canada.
³ Division of Urology, Department of Surgical Oncology, Princess Margaret Cancer Center, University Health Network, University of Toronto, Toronto, ON, Canada.
⁴ Department of Medical Oncology and Hematology, CancerCare Manitoba, University of Manitoba, Winnipeg, MB, Canada.
⁵ Division of Urology, Department of Surgery, University of Ottawa, Ottawa, ON, Canada.
⁶ Department of Surgical Oncology, Princess Margaret Cancer Centre, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
⁷ Departments of Urology and Oncology, Queen's University, Kingston, ON, Canada.
⁸ Department of Radiation Oncology, Radiation Medicine Program, Princess Margaret Hospital, University of Health Network, University of Toronto, Toronto, ON, Canada.
⁹ Division of Medical Oncology, British Columbia Cancer - Vancouver Cancer Centre, University of British Columbia, Vancouver, BC, Canada.
¹⁰ Department of Supportive Care, Princess Margaret Cancer Centre, Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
¹¹ Division of Medical Oncology/Hematology, Le Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
¹² Division of Urology, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada.
¹³ Division of Urology, Department of Surgery, Western University, London, ON, Canada.

PMID: 35905486
PMCID: PMC9343164
DOI: 10.5489/cuaj.8009

No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr. Wood has been an advisory board member for AstraZeneca BMS, Ipsen, Merck, and Pfizer (with no financial compensation); and has participated in clinical trials supported by AstraZeneca, BMS, and Merck (compensation to institution). Dr. Hamilton has been an advisory board member for Astellas, Bayer, Janssen, TerSera; and has participated in clinical trials supported by Astellas, Bayer, Janssen. Dr. Izard has received grants and/or honoraria from Abbvie, Astellas, Bayer, Janssen, and Tolmar; and has participated in clinical trials supported by Astellas, AstraZeneca, Bayer, Janssen, Merck, and Pfizer. Dr. Chung has received honoraria from Abbvie, Boston Scientific, TerSera, and Verity; and has participated in clinical trials supported by CTG, ICON, Medivation, Mount Sinai Health Systems, NRG, and Princess Margaret Cancer Centre. Dr. Nappi has received educational grants from EMD Serono, Ipsen, and Janssen; and has received honoraria from AstraZeneca, Bayer, Ipsen, Janssen, and Pfizer. Dr. Soulières has been an advisory board member for Adlai-Nortye, BMS, Eisai, Ipsen, Merck, and Pfizer; and has received research grants to his institution from BMS, Eisai, Ipsen, Merck, and Pfizer. Dr. Aprikian has been an advisory board member for Abbvie, Astellas, and Bayer; and has received honoraria from Abbvie, Astellas, Bayer, Sanofi, and TerSera. Dr. Canil has been an advisory board member for Bayer, BMS, Eisai, Ipsen, Janssen, Merck, Pfizer, and Seattle Genetics; is a speaker for Janssen; has participated in clinical trials supported by Eisai and Pfizer; and is on the medical advisory board for Kidney Cancer Canada. The remaining authors do not report any competing personal or financial interests related to this work.

References

1. Hanna NH, Einhorn LH. Testicular cancer – discoveries and updates. N Engl J Med. 2014;371:2005–16. doi: 10.1056/NEJMra1407550. - DOI - PubMed
1. Saltzman AF, Cost NG. Adolescent and young adult testicular germ cell tumors: Special considerations. Adv Urol. 2018;2018:2375176. doi: 10.1155/2018/2375176. - DOI - PMC - PubMed
1. Chovanec M, Lauritsen J, Bandak M, et al. Late adverse effects and quality of life in survivors of testicular germ cell tumor. Nat Rev Urol. 2021;18:227–45. doi: 10.1038/s41585-021-00440-w. - DOI - PubMed
1. Hamilton RJ, Canil C, Shrem NS, et al. Canadian Urological Association consensus guideline: Management of testicular germ cell cancer. Can Urol Assoc J. 2022;16:155–73. doi: 10.5489/cuaj.7945. - DOI - PMC - PubMed
1. Feldman DR. State-of-the-art management of germ cell tumors. Am Soc Clin Oncol Educ B. 2018;38:319–23. doi: 10.1200/EDBK_201139. - DOI - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Testicular cancer survivorship: Long-term toxicity and management

Affiliations

Testicular cancer survivorship: Long-term toxicity and management

Authors

Affiliations

Conflict of interest statement

References

Publication types

LinkOut - more resources

Full Text Sources